Cochlear Limited has reduced its FY26 underlying net profit guidance to $290-330 million, down from previous expectations, citing softer-than-expected trading conditions in developed markets and heightened uncertainty from Middle Eastern conflicts. The announcement, made on 22 April 2026, represents a material reassessment of the company’s earnings trajectory and reflects a confluence of operational and macroeconomic headwinds that have emerged since the company’s half-year results in February.
The core issue stems from cochlear implant sales in developed markets, where revenue was flat in the quarter when measured in constant currency. Hospital capacity constraints and reduced referral activity from the hearing aid channel have combined to suppress near-term surgical volumes. Consumer sentiment has deteriorated markedly, with the US experiencing historic lows that appear to be influencing discretionary healthcare decisions, particularly in the adult and seniors segment where Cochlear has been targeting growth. Western Europe presents additional challenges, with surgical waiting lists growing in the UK and Germany, while industrial action in Italy and Spain has further constrained throughput.
The Middle East conflict introduces an additional layer of uncertainty for the company’s emerging markets business. Cochlear expects order cancellations and delivery delays in the region, creating potential provisions for receivables that will weigh on second-half profitability. Combined with lower gross margins, expenses associated with reshaping the cost base, and currency headwinds from a stronger Australian dollar, these factors have forced a material repricing of full-year earnings expectations. Second-half sales growth is now projected at 2-6 percent in constant currency, a substantial deceleration from historical trends.
Despite the near-term challenges, management has sought to maintain confidence in the company’s strategic direction. Cochlear is accelerating plans to reshape its cost base to free up capacity for growth investments, particularly in the adult and seniors segment. The company highlights strong adoption of its Nucleus Nexa System with improving market share following the completion of contracting for the new system. The R&D pipeline remains robust, with clinical studies for a drug-eluting electrode in their final recruitment phase and totally implantable cochlear implant trials underway.
For investors, the guidance reduction underscores the vulnerability of Cochlear’s near-term growth to demand-side shocks and macroeconomic sensitivity. The discretionary nature of adult hearing loss treatment and the company’s exposure to geopolitical risk in the Middle East represent material uncertainties. However, the medium-term opportunity remains intact if management can successfully execute its strategy to medicalise hearing loss and bring next-generation technologies to market.
The critical metrics to monitor in coming quarters include whether second-half sales growth lands within the 2-6 percent constant currency range provided, the extent of Middle Eastern revenue impact, and progress on the clinical studies for next-generation implants. The announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Cochlear Limited (ASX: COH)
Cochlear Limited is the world’s leading manufacturer of cochlear implant devices and other implantable hearing solutions for individuals with severe to profound hearing loss. The company develops and manufactures cochlear implant systems, bone conduction devices, sound processors, and related accessories for children and adults worldwide. Headquartered in Sydney, Australia, Cochlear operates across developed markets in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
